Recruiting

rTMS

Sponsor:

The Methodist Hospital Research Institute

Code:

NCT07948330

Conditions

Urinary Incontinence

Prostate Treatment

Incontinence After Prostate Treatment

Eligibility Criteria

Sex: Male

Age: 22 - 70+

Healthy Volunteers: Accepted

Interventions

Magstim - rTMS system

Baseline Imaging and Questionnaires

Study Details

Brief summary:

Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies.

Conditions

Urinary Incontinence

Prostate Treatment

Incontinence After Prostate Treatment

Study ID

NCT07948330

Start date

Sep 16, 2026

Status verified date

Nov, 2026

Completion date

Oct 1, 2027

Anticipated

Primary completion date

Oct 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 22 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria (IPT Cohort):

  • Adult males (biological sex at birth), aged 22 to 80 years.
  • History of prostate treatment (e.g., radical prostatectomy, TURP, HoLEP, Aquablation, water vapor therapy, photoselective vaporization) ≥ 6 months prior.
  • Answers "yes" to any sub-item of Question 6 on the ICIQ-UI SF ("When does urine leak?", such as leaks before reaching the toilet, cough/sneeze, during sleep, physical activity, post-void dribbling, or no obvious reason).
  • Montreal Cognitive Assessment (MoCA) score > 10.
  • Eligible per MRI safety screening questionnaire.

Inclusion Criteria (Continent Control):

  • Adult males (biological sex at birth), aged 22 to 80 years.
  • History of prostate treatment ≥ 6 months prior.
  • Selects only "never - urine does not leak" on Question 6 of the ICIQ-UI SF and has a total score = 0.
  • Montreal Cognitive Assessment (MoCA) score > 10.
  • Eligible per MRI safety screening questionnaire.

Exclusion Criteria:

  • Answers "never" to Question 6 of the ICIQ-UI SF (for IPT cohort) or answers "yes" to any sub-item (for continent cohort).
  • Contraindications to MRI.
  • Contraindications to rTMS (personal or immediate family history of seizure disorder, implanted electronic devices or conductive objects in or near the head).
  • Active urinary tract infection (UTI) at screening (eligible after adequate treatment).
  • Intradetrusor onabotulinumtoxinA injection within the past 6 months.
  • Active use of sacral neurostimulator (SNS) or posterior tibial nerve stimulation (TNS) (history allowed if last stimulation was > 3 months prior).
  • Clinically diagnosed neurological disorders (e.g., Multiple Sclerosis, Parkinson's disease, cerebral aneurysm, hydrocephalus, spinal cord injury with motor/sensory deficits, or advanced dementia defined by MoCA > 10).
  • Parenchymal brain lesions and hemorrhagic stroke within the last 12 months. Taking medications that lower seizure threshold (e.g., bupropion) or heavy alcohol use.
  • Diagnosis of interstitial cystitis, history of pelvic radiation, or bladder augmentation.
  • Post-void residual (PVR) > 250 cc.
  • Incarcerated individuals.

Study Design

Enrollment

23 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: High-Frequency rTMS (Excitatory)

Participants receive high-frequency (excitatory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes total.

experimental: Low-Frequency rTMS (Inhibitory)

Participants receive low-frequency (inhibitory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes.

other: Continent Controls

Non-interventional Control Group undergoing questionnaires and baseline imaging (fMRI)

Interventions

Magstim - rTMS system

The Magstim Rapid2 system is a magnetic stimulation system capable of selectively inducing, modulating, or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS. Utilizing the StimGuide navigation system, the investigators will accurately target the pelvic supplementary motor area (pSMA). The Magstim Rapid2 system is used in this study to deliver either high-frequency (excitatory) or low-frequency (inhibitory) rTMS to assess physiological and neurofunctional effects on continence control in men with incontinence after prostate treatment (IPT).

Baseline Imaging and Questionnaires

Non-interventional control consistent of questionnaires and baseline brain functional MRI (fMRI) with no rTMS stimulation.

Primary outcome measure

  • Recruitment and Retention Rate [ Time Frame: From enrollment through the 1-month follow-up visit (approximately 2 to 3 months total per participant) ]
  • Acceptability of Intervention [ Time Frame: Immediately after the single rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment) ]
  • Adverse Events [ Time Frame: From informed consent through the 1-month virtual follow-up visit ]

Central Contacts and Locations

Central contacts

Locations

Houston Methodist Hospital

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Rose Khavari, MD

More Information

Sponsor

The Methodist Hospital Research Institute

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • functional neuroimaging
  • repetitive transcranial magnetic stimulation
  • neuromodulation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by The Methodist Hospital Research Institute on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.